;PMID: 2848026
;source_file_1804.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..41] = [t:0..41]
;1)sentence:[e:47..184] = [t:47..184]
;2)section:[e:188..218] = [t:188..218]
;3)section:[e:222..298] = [t:222..298]
;4)sentence:[e:302..563] = [t:302..563]
;5)sentence:[e:564..697] = [t:564..697]
;6)sentence:[e:698..814] = [t:698..814]
;7)sentence:[e:815..940] = [t:815..940]
;8)sentence:[e:941..1142] = [t:941..1142]
;9)sentence:[e:1143..1429] = [t:1143..1429]
;10)sentence:[e:1430..1708] = [t:1430..1708]
;11)sentence:[e:1709..1833] = [t:1709..1833]
;12)sentence:[e:1834..2007] = [t:1834..2007]
;13)sentence:[e:2008..2119] = [t:2008..2119]
;14)sentence:[e:2120..2210] = [t:2120..2210]
;15)sentence:[e:2211..2292] = [t:2211..2292]
;16)section:[e:2296..2340] = [t:2296..2340]

;section 0 Span:0..41
;J Biol Chem. 1988 Dec 5;263(34):18138-42.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..6] Biol) (NNP:[7..11] Chem) (.:[11..12] .)
        (CD:[13..17] 1988) (NNP:[18..21] Dec) (CC:[22..28] 5;263-LRB-)
        (CD:[28..30] 34) (-RRB-:[30..31] -RRB-) (::[31..32] :)
        (CD:[32..40] 18138-42) (.:[40..41] .)))

;sentence 1 Span:47..184
;Purification and characterization of 5 beta-cholestane-3 alpha,7 alpha,12 
;alpha-triol 27-hydroxylase from female rat liver mitochondria.
;[84..148]:cyp450:"5 beta-cholestane-3 alpha,7 alpha,12  alpha-triol
;27-hydroxylase"
(SENT
  (NP-HLN
    (NP (NN:[47..59] Purification) (CC:[60..63] and)
        (NN:[64..80] characterization))
    (PP (IN:[81..83] of)
      (NP
        (NP (CD:[84..85] 5) (NN:[86..103] beta-cholestane-3)
            (NN:[104..111] alpha,7) (NN:[112..120] alpha,12)
            (NN:[122..133] alpha-triol) (NN:[134..148] 27-hydroxylase))
        (PP (IN:[149..153] from)
          (NP (JJ:[154..160] female) (NN:[161..164] rat) (NN:[165..170] liver)
              (NNS:[171..183] mitochondria)))))
    (.:[183..184] .)))

;section 2 Span:188..218
;Okuda K, Masumoto O, Ohyama Y.
(SEC
  (FRAG (NNP:[188..193] Okuda) (NNP:[194..196] K,) (NNP:[197..205] Masumoto)
        (NNP:[206..207] O) (,:[207..208] ,) (NNP:[209..215] Ohyama)
        (NNP:[216..217] Y) (.:[217..218] .)))

;section 3 Span:222..298
;Department of Biochemistry, Hiroshima University School of Dentistry, Japan.
(SEC
  (FRAG (NNP:[222..232] Department) (IN:[233..235] of)
        (NNP:[236..248] Biochemistry) (,:[248..249] ,)
        (NNP:[250..259] Hiroshima) (NNP:[260..270] University)
        (NNP:[271..277] School) (IN:[278..280] of) (NNP:[281..290] Dentistry)
        (,:[290..291] ,) (NNP:[292..297] Japan) (.:[297..298] .)))

;sentence 4 Span:302..563
;5 beta-Cholestane-3 alpha,7 alpha,12 alpha-triol 27-hydroxylase (5 
;beta-cholestane-3 alpha,7 alpha,12 alpha-triol, NADPH:oxygen oxidoreductase 
;(26-hydroxylating), EC 1.14.13.15) was purified from female rat liver 
;mitochondria based on its catalytic activity.
;[302..365]:cyp450:"5 beta-Cholestane-3 alpha,7 alpha,12 alpha-triol
;27-hydroxylase"
;[367..416]:substance:"5  beta-cholestane-3 alpha,7 alpha,12 alpha-triol"
;[418..445]:substance:"NADPH:oxygen oxidoreductase"
(SENT
  (S
    (NP-SBJ-1
      (NP (CD:[302..303] 5) (NN:[304..321] beta-Cholestane-3)
          (NN:[322..329] alpha,7) (NN:[330..338] alpha,12)
          (NN:[339..350] alpha-triol) (NN:[351..365] 27-hydroxylase))
      (NP (-LRB-:[366..367] -LRB-)
        (NP (CD:[367..368] 5) (NN:[370..387] beta-cholestane-3)
            (NN:[388..395] alpha,7) (NN:[396..404] alpha,12)
            (NN:[405..416] alpha-triol))
        (,:[416..417] ,)
        (NP
          (NP
            (NML (NN:[418..423] NADPH) (SYM:[423..424] :) (NN:[424..430] oxygen))
            (NN:[431..445] oxidoreductase))
          (NP (-LRB-:[447..448] -LRB-) (VBG:[448..464] 26-hydroxylating)
              (-RRB-:[464..465] -RRB-)))
        (,:[465..466] ,)
        (NP (NNP:[467..469] EC) (CD:[470..480] 1.14.13.15))
        (-RRB-:[480..481] -RRB-)))
    (VP (VBD:[482..485] was)
      (VP (VBN:[486..494] purified)
        (NP-1 (-NONE-:[494..494] *))
        (PP (IN:[495..499] from)
          (NP (JJ:[500..506] female) (NN:[507..510] rat) (NN:[511..516] liver)
              (NNS:[518..530] mitochondria)))
        (S-ADV
          (NP-SBJ (-NONE-:[530..530] *))
          (VP (VBN:[531..536] based)
            (NP (-NONE-:[536..536] *))
            (PP-CLR (IN:[537..539] on)
              (NP (PRP$:[540..543] its) (JJ:[544..553] catalytic)
                  (NN:[554..562] activity)))))))
    (.:[562..563] .)))

;sentence 5 Span:564..697
;The final preparation of the  enzyme showed a single major band on the sodium
;dodecyl sulfate-polyacrylamide  gel electrophoretogram.
;[594..600]:substance:"enzyme"
;[635..657]:substance:"sodium dodecyl sulfate"
;[658..672]:substance:"polyacrylamide"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[564..567] The) (JJ:[568..573] final) (NN:[574..585] preparation))
      (PP (IN:[586..588] of)
        (NP (DT:[589..592] the) (NN:[594..600] enzyme))))
    (VP (VBD:[601..607] showed)
      (NP (DT:[608..609] a) (JJ:[610..616] single) (JJ:[617..622] major)
          (NN:[623..627] band))
      (PP-LOC (IN:[628..630] on)
        (NP (DT:[631..634] the)
          (NML
            (NML
              (NML (NN:[635..641] sodium) (NN:[642..649] dodecyl)
                   (NN:[650..657] sulfate))
              (HYPH:[657..658] -) (NN:[658..672] polyacrylamide))
            (NN:[674..677] gel))
          (NN:[678..696] electrophoretogram))))
    (.:[696..697] .)))

;sentence 6 Span:698..814
;The content of purified enzyme was 12 nmol/mg of  protein, and the specific
;activity was 431 nmol/min/mg of protein.
;[722..728]:substance:"enzyme"
;[733..735]:quantitative-value:"12"
;[736..755]:quantitative-units:"nmol/mg of  protein"
;[787..790]:quantitative-value:"431"
;[791..813]:quantitative-units:"nmol/min/mg of protein"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (DT:[698..701] The) (NN:[702..709] content))
        (PP (IN:[710..712] of)
          (NP (VBN:[713..721] purified) (NN:[722..728] enzyme))))
      (VP (VBD:[729..732] was)
        (NP-PRD
          (NP (CD:[733..735] 12) (NN:[736..740] nmol))
          (PP (SYM:[740..741] /)
            (NP
              (NP (NN:[741..743] mg))
              (PP (IN:[744..746] of)
                (NP (NN:[748..755] protein))))))))
    (,:[755..756] ,) (CC:[757..760] and)
    (S
      (NP-SBJ (DT:[761..764] the) (JJ:[765..773] specific)
              (NN:[774..782] activity))
      (VP (VBD:[783..786] was)
        (NP-PRD
          (NP (CD:[787..790] 431) (NN:[791..795] nmol))
          (PP (SYM:[795..796] /)
            (NP (NN:[796..799] min)))
          (PP (SYM:[799..800] /)
            (NP
              (NP (NN:[800..802] mg))
              (PP (IN:[803..805] of)
                (NP (NN:[806..813] protein))))))))
    (.:[813..814] .)))

;sentence 7 Span:815..940
;The molecular  weight of the enzyme was determined from sodium dodecyl
;sulfate-polyacrylamide  gel electrophoresis as 52,500.
;[844..850]:substance:"enzyme"
;[871..893]:substance:"sodium dodecyl sulfate"
;[894..908]:substance:"polyacrylamide"
;[933..939]:quantitative-value:"52,500"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[815..818] The) (JJ:[819..828] molecular) (NN:[830..836] weight))
      (PP (IN:[837..839] of)
        (NP (DT:[840..843] the) (NN:[844..850] enzyme))))
    (VP (VBD:[851..854] was)
      (VP (VBN:[855..865] determined)
        (NP-1 (-NONE-:[865..865] *))
        (PP (IN:[866..870] from)
          (NP
            (NML
              (NML
                (NML (NN:[871..877] sodium) (NN:[878..885] dodecyl)
                     (NN:[886..893] sulfate))
                (HYPH:[893..894] -) (NN:[894..908] polyacrylamide))
              (NN:[910..913] gel))
            (NN:[914..929] electrophoresis)))
        (PP (IN:[930..932] as)
          (NP (CD:[933..939] 52,500)))))
    (.:[939..940] .)))

;sentence 8 Span:941..1142
;The absorption spectra of the purified enzyme and  that of the
;dithionite-reduced CO complex showed peaks at 417 and 450 nm,  respectively,
;indicating the enzyme belongs to the cytochrome P-450 family.
;[980..986]:cyp450:"enzyme"
;[1004..1014]:substance:"dithionite"
;[1023..1033]:substance:"CO complex"
;[1050..1053]:quantitative-value:"417"
;[1058..1061]:quantitative-value:"450"
;[1062..1064]:quantitative-units:"nm"
;[1096..1102]:cyp450:"enzyme"
;[1118..1134]:cyp450:"cytochrome P-450"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (DT:[941..944] The) (NN:[945..955] absorption)
            (NNS:[956..963] spectra))
        (PP (IN:[964..966] of)
          (NP (DT:[967..970] the) (VBN:[971..979] purified)
              (NN:[980..986] enzyme))))
      (CC:[987..990] and)
      (NP
        (NP (DT:[992..996] that))
        (PP (IN:[997..999] of)
          (NP (DT:[1000..1003] the)
            (ADJP (NN:[1004..1014] dithionite) (HYPH:[1014..1015] -)
                  (VBN:[1015..1022] reduced))
             (NN:[1023..1025] CO) (NN:[1026..1033] complex)))))
    (VP (VBD:[1034..1040] showed)
      (NP (NNS:[1041..1046] peaks))
      (PP-LOC (IN:[1047..1049] at)
        (NP
          (NP (CD:[1050..1053] 417)
            (NML-1 (-NONE-:[1053..1053] *P*)))
          (CC:[1054..1057] and)
          (NP (CD:[1058..1061] 450)
            (NML-1 (NN:[1062..1064] nm)))))
      (,:[1064..1065] ,)
      (ADVP (RB:[1067..1079] respectively))
      (,:[1079..1080] ,)
      (S-MNR
        (NP-SBJ (-NONE-:[1080..1080] *))
        (VP (VBG:[1081..1091] indicating)
          (SBAR (-NONE-:[1091..1091] 0)
            (S
              (NP-SBJ (DT:[1092..1095] the) (NN:[1096..1102] enzyme))
              (VP (VBZ:[1103..1110] belongs)
                (PP-CLR (TO:[1111..1113] to)
                  (NP (DT:[1114..1117] the)
                    (NML (NN:[1118..1128] cytochrome) (NN:[1129..1134] P-450))
                    (NN:[1135..1141] family)))))))))
    (.:[1141..1142] .)))

;sentence 9 Span:1143..1429
;Upon  reconstitution with the electron-transferring system of the adrenal
;(adrenodoxin  and NADPH-adrenodoxin reductase), the enzyme showed high
;activity hydroxylating  5 beta-cholestane-3 alpha,7 alpha-12-triol at
;position 27 with a turnover number  of 35.5 min-1 and Km of 6.3 microM.
;[1218..1229]:substance:"adrenodoxin"
;[1235..1262]:substance:"NADPH-adrenodoxin reductase"
;[1269..1275]:substance:"enzyme"
;[1312..1354]:substance:"5 beta-cholestane-3 alpha,7 alpha-12-triol"
;[1397..1401]:quantitative-value:"35.5"
;[1402..1407]:quantitative-units:"min-1"
;[1412..1414]:quantitative-name:"Km"
;[1418..1421]:quantitative-value:"6.3"
;[1422..1428]:quantitative-units:"microM"
(SENT
  (S
    (PP-TMP (IN:[1143..1147] Upon)
      (NP
        (NP (NN:[1149..1163] reconstitution))
        (PP (IN:[1164..1168] with)
          (NP
            (NP (DT:[1169..1172] the)
              (ADJP (NN:[1173..1181] electron) (HYPH:[1181..1182] -)
                    (VBG:[1182..1194] transferring))
              (NN:[1195..1201] system))
            (PP (IN:[1202..1204] of)
              (NP (DT:[1205..1208] the) (JJ:[1209..1216] adrenal)
                (PRN (-LRB-:[1217..1218] -LRB-)
                  (NP
                    (NP (NN:[1218..1229] adrenodoxin))
                    (CC:[1231..1234] and)
                    (NP
                      (NML (NN:[1235..1240] NADPH) (HYPH:[1240..1241] -)
                           (NN:[1241..1252] adrenodoxin))
                      (NN:[1253..1262] reductase)))
                  (-RRB-:[1262..1263] -RRB-))))))))
    (,:[1263..1264] ,)
    (NP-SBJ (DT:[1265..1268] the) (NN:[1269..1275] enzyme))
    (VP (VBD:[1276..1282] showed)
      (NP
        (NP (JJ:[1283..1287] high) (NN:[1288..1296] activity))
        (VP (VBG:[1297..1310] hydroxylating)
          (NP (CD:[1312..1313] 5) (NN:[1314..1331] beta-cholestane-3)
              (NN:[1332..1339] alpha,7) (NN:[1340..1354] alpha-12-triol))
          (PP-LOC (IN:[1355..1357] at)
            (NP (NN:[1358..1366] position) (CD:[1367..1369] 27)))
          (PP (IN:[1370..1374] with)
            (NP
              (NP
                (NP (DT:[1375..1376] a) (NN:[1377..1385] turnover)
                    (NN:[1386..1392] number))
                (PP (IN:[1394..1396] of)
                  (NP (CD:[1397..1401] 35.5) (NN:[1402..1407] min-1))))
              (CC:[1408..1411] and)
              (NP
                (NP (NN:[1412..1414] Km))
                (PP (IN:[1415..1417] of)
                  (NP (CD:[1418..1421] 6.3) (NN:[1422..1428] microM)))))))))
    (.:[1428..1429] .)))

;sentence 10 Span:1430..1708
;The enzyme activity was completely lost when  the electron-transferring
;system was replaced by that of microsomes  (NADPH-cytochrome P-450 reductase
;purified from rat liver microsomes),  confirming that the P-450 enzyme was of
;the mitochondrial type, but not of the  microsomal.
;[1434..1440]:substance:"enzyme"
;[1546..1578]:substance:"NADPH-cytochrome P-450 reductase"
;[1637..1649]:cyp450:"P-450 enzyme"
(SENT
  (S
    (NP-SBJ-5 (DT:[1430..1433] The) (NN:[1434..1440] enzyme)
              (NN:[1441..1449] activity))
    (VP (VBD:[1450..1453] was)
      (ADVP-EXT (RB:[1454..1464] completely))
      (VP (VBN:[1465..1469] lost)
        (NP-5 (-NONE-:[1469..1469] *))
        (SBAR-ADV
          (WHADVP-4 (WRB:[1470..1474] when))
          (S
            (NP-SBJ-3 (DT:[1476..1479] the)
              (ADJP (NN:[1480..1488] electron) (HYPH:[1488..1489] -)
                    (VBG:[1489..1501] transferring))
              (NN:[1502..1508] system))
            (VP (VBD:[1509..1512] was)
              (VP (VBN:[1513..1521] replaced)
                (NP-3 (-NONE-:[1521..1521] *))
                (PP (IN:[1522..1524] by)
                  (NP-LGS
                    (NP (DT:[1525..1529] that))
                    (PP (IN:[1530..1532] of)
                      (NP (NNS:[1533..1543] microsomes)
                        (PRN (-LRB-:[1545..1546] -LRB-)
                          (NP
                            (NP
                              (NML
                                (NML (NN:[1546..1551] NADPH))
                                (HYPH:[1551..1552] -)
                                (NML (NN:[1552..1562] cytochrome)
                                     (NN:[1563..1568] P-450)))
                              (NN:[1569..1578] reductase))
                            (VP (VBN:[1579..1587] purified)
                              (NP (-NONE-:[1587..1587] *))
                              (PP (IN:[1588..1592] from)
                                (NP (NN:[1593..1596] rat)
                                    (NN:[1597..1602] liver)
                                    (NNS:[1603..1613] microsomes)))))
                          (-RRB-:[1613..1614] -RRB-))))))
                (,:[1614..1615] ,)
                (S-ADV
                  (NP-SBJ (-NONE-:[1615..1615] *))
                  (VP (VBG:[1617..1627] confirming)
                    (SBAR (IN:[1628..1632] that)
                      (S
                        (NP-SBJ (DT:[1633..1636] the)
                           (NN:[1637..1642] P-450) (NN:[1643..1649] enzyme))
                        (VP
                          (VP (VBD:[1650..1653] was)
                            (PP-PRD (IN:[1654..1656] of)
                              (NP=1 (DT:[1657..1660] the)
                                    (JJ:[1661..1674] mitochondrial)
                                    (NN:[1675..1679] type))))
                          (,:[1679..1680] ,) (CC:[1681..1684] but)
                          (VP (RB:[1685..1688] not)
                            (PP-PRD (IN:[1689..1691] of)
                              (NP=1 (DT:[1692..1695] the)
                                    (JJ:[1697..1707] microsomal)))))))))))))))
    (.:[1707..1708] .)))

;sentence 11 Span:1709..1833
;The omission of cytochrome P-450, adrenodoxin, or NADPH-adrenodoxin 
;reductase resulted in complete loss of enzyme activity.
;[1725..1741]:cyp450:"cytochrome P-450"
;[1743..1754]:substance:"adrenodoxin"
;[1759..1787]:substance:"NADPH-adrenodoxin  reductase"
;[1817..1823]:substance:"enzyme"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1709..1712] The) (NN:[1713..1721] omission))
      (PP (IN:[1722..1724] of)
        (NP
          (NP (NN:[1725..1735] cytochrome) (NN:[1736..1741] P-450))
          (,:[1741..1742] ,)
          (NP (NN:[1743..1754] adrenodoxin))
          (,:[1754..1755] ,) (CC:[1756..1758] or)
          (NP
            (NML (NN:[1759..1764] NADPH) (HYPH:[1764..1765] -)
                 (NN:[1765..1776] adrenodoxin))
            (NN:[1778..1787] reductase)))))
    (VP (VBD:[1788..1796] resulted)
      (PP-CLR (IN:[1797..1799] in)
        (NP
          (NP (JJ:[1800..1808] complete) (NN:[1809..1813] loss))
          (PP (IN:[1814..1816] of)
            (NP (NN:[1817..1823] enzyme) (NN:[1824..1832] activity))))))
    (.:[1832..1833] .)))

;sentence 12 Span:1834..2007
;The specific activity  toward 5 beta-cholestane-3 alpha, 7 alpha-diol was
;less than one-half that  toward cholestanetriol and that toward cholesterol
;was about one-fiftieth.
;[1864..1903]:substance:"5 beta-cholestane-3 alpha, 7 alpha-diol"
;[1940..1955]:substance:"cholestanetriol"
;[1972..1983]:substance:"cholesterol"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (DT:[1834..1837] The) (JJ:[1838..1846] specific)
            (NN:[1847..1855] activity))
        (PP (IN:[1857..1863] toward)
          (NP (CD:[1864..1865] 5) (NN:[1866..1883] beta-cholestane-3)
              (SYM:[1884..1889] alpha) (,:[1889..1890] ,) (CD:[1891..1892] 7)
              (NN:[1893..1903] alpha-diol))))
      (VP (VBD:[1904..1907] was)
        (NP-PRD
          (NP
            (QP (JJR:[1908..1912] less) (IN:[1913..1917] than)
                (CD:[1918..1921] one) (HYPH:[1921..1922] -)
                (NN:[1922..1926] half))
            (DT:[1927..1931] that))
          (PP (IN:[1933..1939] toward)
            (NP (NN:[1940..1955] cholestanetriol))))))
    (CC:[1956..1959] and)
    (S
      (NP-SBJ
        (NP (DT:[1960..1964] that))
        (PP (IN:[1965..1971] toward)
          (NP (NN:[1972..1983] cholesterol))))
      (VP (VBD:[1984..1987] was)
        (NP-PRD
          (QP (RB:[1988..1993] about) (CD:[1994..1997] one)
              (HYPH:[1997..1998] -) (NN:[1998..2006] fiftieth)))))
    (.:[2006..2007] .)))

;sentence 13 Span:2008..2119
;The  enzyme showed no activity toward xenobiotics such as benzphetamine, 
;7-ethoxycoumarin, and benzo[a]pyrene.
;[2013..2019]:substance:"enzyme"
;[2046..2057]:substance:"xenobiotics"
;[2066..2079]:substance:"benzphetamine"
;[2082..2098]:substance:"7-ethoxycoumarin"
;[2104..2118]:substance:"benzo[a]pyrene"
(SENT
  (S
    (NP-SBJ (DT:[2008..2011] The) (NN:[2013..2019] enzyme))
    (VP (VBD:[2020..2026] showed)
      (NP
        (NP (DT:[2027..2029] no) (NN:[2030..2038] activity))
        (PP (IN:[2039..2045] toward)
          (NP
            (NP (NNS:[2046..2057] xenobiotics))
            (PP (JJ:[2058..2062] such) (IN:[2063..2065] as)
              (NP (NN:[2066..2079] benzphetamine) (,:[2079..2080] ,)
                  (NN:[2082..2098] 7-ethoxycoumarin) (,:[2098..2099] ,)
                  (CC:[2100..2103] and) (NN:[2104..2118] benzo-LSB-a-RSB-pyrene)))))))
    (.:[2118..2119] .)))

;sentence 14 Span:2120..2210
;Its activity was not inhibited by  metyrapone and slightly inhibited by
;aminoglutethimide.
;[2155..2165]:substance:"metyrapone"
;[2192..2209]:substance:"aminoglutethimide"
(SENT
  (S
    (NP-SBJ-1 (PRP$:[2120..2123] Its) (NN:[2124..2132] activity))
    (VP (VBD:[2133..2136] was)
      (VP
        (VP (RB:[2137..2140] not) (VBN:[2141..2150] inhibited)
          (NP-1 (-NONE-:[2150..2150] *))
          (PP (IN:[2151..2153] by)
            (NP-LGS (NN:[2155..2165] metyrapone))))
        (CC:[2166..2169] and)
        (VP
          (ADVP-EXT (RB:[2170..2178] slightly))
          (VBN:[2179..2188] inhibited)
          (NP-1 (-NONE-:[2188..2188] *))
          (PP (IN:[2189..2191] by)
            (NP-LGS (NN:[2192..2209] aminoglutethimide))))))
    (.:[2209..2210] .)))

;sentence 15 Span:2211..2292
;The enzyme activity was  markedly lowered in an atmosphere of CO/O2/N2,
;40/20/40.
;[2215..2221]:substance:"enzyme"
;[2273..2275]:substance:"CO"
;[2276..2278]:substance:"O2"
;[2279..2281]:substance:"N2"
(SENT
  (S
    (NP-SBJ-1 (DT:[2211..2214] The) (NN:[2215..2221] enzyme)
              (NN:[2222..2230] activity))
    (VP (VBD:[2231..2234] was)
      (ADVP-MNR (RB:[2236..2244] markedly))
      (VP (VBN:[2245..2252] lowered)
        (NP-1 (-NONE-:[2252..2252] *))
        (PP-LOC (IN:[2253..2255] in)
          (NP
            (NP (DT:[2256..2258] an) (NN:[2259..2269] atmosphere))
            (PP (IN:[2270..2272] of)
              (NP
                (NP (NN:[2273..2275] CO) (SYM:[2275..2276] /)
                    (NN:[2276..2278] O2) (SYM:[2278..2279] /)
                    (NN:[2279..2281] N2))
                (,:[2281..2282] ,)
                (NP (CD:[2283..2285] 40) (SYM:[2285..2286] /)
                    (CD:[2286..2288] 20) (SYM:[2288..2289] /)
                    (CD:[2289..2291] 40))))))))
    (.:[2291..2292] .)))

;section 16 Span:2296..2340
;PMID: 2848026 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2296..2300] PMID) (::[2300..2301] :) (CD:[2302..2309] 2848026)
        (NN:[2310..2311] -LSB-) (NNP:[2311..2317] PubMed) (::[2318..2319] -)
        (NN:[2320..2327] indexed) (IN:[2328..2331] for)
        (NNP:[2332..2340] MEDLINE-RSB-)))
